Development of large-scale nucleic acid synthesis using hybrid substrates (Q4417969): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Changed label, description and/or aliases in en, and other parts) |
||||||||||||||
| label / en | label / en | ||||||||||||||
Development of large-scale nucleic acid synthesis using hybrid substrates | |||||||||||||||
| Property / summary | |||||||||||||||
The aim of the project is to increase the synthesis of nucleic acids from 0.2 µmol to 25 µmol, so that synthetic oligonucleotides can be obtained in at least milligram amounts. The goal will be achieved by developing a new type of hybrid substrates in the glass-silan-polymer system for effective large-scale synthesis of oligonucleotides and by simplifying the chromatographic method for the purification of nucleic acids. Synthetic substrates will combine the advantages of solid-phase synthesis and better penetration of reactive sites by the reagents provided by the polymer phase. Thanks to the use of the new synthetic reactor, we will prevent adverse factors occurring in the expansion of the synthesis scale, such as: bonding of the substrate, low penetration, swelling or degradation. By chemical modification of the chromatographic deposit with organo-functional silates, we will obtain an increased affinity for oligonucleotides purified by the “DMT-ON” method. Thanks to the tests carried out in the field of hybrid substrates, modification of chromatographic deposits and a new reactor, we will carry out demonstration synthesis on a scale of at least 25 µmola. The conclusions of the demonstration will be transferred to the synthesis of oligonucleotides, so that in one technological gray it receives > 100 mg with a purity of > 95 %. The growing demand for large amounts of oligonucleotides associated, among others, with their use in the pharmaceutical industry (e.g. antigen therapies) or diagnostic (e.g. genetic tests) forces the taking of measures enabling the development of this niche. Currently, the market lacks suppliers of oligonucleotides in milligram/gram quantities. “SA.41471(2015/X) Purpose of public aid: art: 25 EC Regulation No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L 119, p. That’s it. EU L 187/1 of 26.06.2014)’. (English) | |||||||||||||||
| Property / summary: The aim of the project is to increase the synthesis of nucleic acids from 0.2 µmol to 25 µmol, so that synthetic oligonucleotides can be obtained in at least milligram amounts. The goal will be achieved by developing a new type of hybrid substrates in the glass-silan-polymer system for effective large-scale synthesis of oligonucleotides and by simplifying the chromatographic method for the purification of nucleic acids. Synthetic substrates will combine the advantages of solid-phase synthesis and better penetration of reactive sites by the reagents provided by the polymer phase. Thanks to the use of the new synthetic reactor, we will prevent adverse factors occurring in the expansion of the synthesis scale, such as: bonding of the substrate, low penetration, swelling or degradation. By chemical modification of the chromatographic deposit with organo-functional silates, we will obtain an increased affinity for oligonucleotides purified by the “DMT-ON” method. Thanks to the tests carried out in the field of hybrid substrates, modification of chromatographic deposits and a new reactor, we will carry out demonstration synthesis on a scale of at least 25 µmola. The conclusions of the demonstration will be transferred to the synthesis of oligonucleotides, so that in one technological gray it receives > 100 mg with a purity of > 95 %. The growing demand for large amounts of oligonucleotides associated, among others, with their use in the pharmaceutical industry (e.g. antigen therapies) or diagnostic (e.g. genetic tests) forces the taking of measures enabling the development of this niche. Currently, the market lacks suppliers of oligonucleotides in milligram/gram quantities. “SA.41471(2015/X) Purpose of public aid: art: 25 EC Regulation No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L 119, p. That’s it. EU L 187/1 of 26.06.2014)’. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The aim of the project is to increase the synthesis of nucleic acids from 0.2 µmol to 25 µmol, so that synthetic oligonucleotides can be obtained in at least milligram amounts. The goal will be achieved by developing a new type of hybrid substrates in the glass-silan-polymer system for effective large-scale synthesis of oligonucleotides and by simplifying the chromatographic method for the purification of nucleic acids. Synthetic substrates will combine the advantages of solid-phase synthesis and better penetration of reactive sites by the reagents provided by the polymer phase. Thanks to the use of the new synthetic reactor, we will prevent adverse factors occurring in the expansion of the synthesis scale, such as: bonding of the substrate, low penetration, swelling or degradation. By chemical modification of the chromatographic deposit with organo-functional silates, we will obtain an increased affinity for oligonucleotides purified by the “DMT-ON” method. Thanks to the tests carried out in the field of hybrid substrates, modification of chromatographic deposits and a new reactor, we will carry out demonstration synthesis on a scale of at least 25 µmola. The conclusions of the demonstration will be transferred to the synthesis of oligonucleotides, so that in one technological gray it receives > 100 mg with a purity of > 95 %. The growing demand for large amounts of oligonucleotides associated, among others, with their use in the pharmaceutical industry (e.g. antigen therapies) or diagnostic (e.g. genetic tests) forces the taking of measures enabling the development of this niche. Currently, the market lacks suppliers of oligonucleotides in milligram/gram quantities. “SA.41471(2015/X) Purpose of public aid: art: 25 EC Regulation No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L 119, p. That’s it. EU L 187/1 of 26.06.2014)’. (English) / qualifier | |||||||||||||||
point in time: 21 October 2022
| |||||||||||||||
Revision as of 12:20, 21 October 2022
Project Q4417969 in Poland
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of large-scale nucleic acid synthesis using hybrid substrates |
Project Q4417969 in Poland |
Statements
4,490,006.29 zloty
0 references
998,128.4 Euro
0 references
5,091,143.05 zloty
0 references
1,131,761.1 Euro
0 references
88.19 percent
0 references
1 January 2021
0 references
31 December 2023
0 references
FUTURESYNTHESIS SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
0 references
Celem projektu jest zwiększenie skali syntezy kwasów nukleinowych ze skali 0,2 µmola do skali 25 µmoli, dzięki czemu możliwe będzie otrzymanie syntetycznych oligonukleotydów w ilościach co najmniej miligramowych. Cel zostanie osiągnięty poprzez opracowanie nowego typu podłoży hybrydowych w układzie kulka szklana-silan-polimer do efektywnej wielkoskalowej syntezy oligonukleotydów oraz uproszczenie metody chromatograficznego oczyszczania kwasów nukleinowych. Podłoża syntetyczne łączyć będą zalety syntezy na fazie stałej oraz lepszej penetracji miejsc reaktywnych przez reagenty, którą dostarcza faza polimerowa. Dzięki zastosowaniu nowego reaktora syntetycznego zapobiegniemy niekorzystnym czynnikom występującym w powiększaniu skali syntezy takich jak: sklejanie się podłoża, niska penetracja, pęcznienie czy degradacja. Poprzez chemiczną modyfikację złoża chromatograficznego za pomocą organo-funkcyjnych silanów uzyskamy zwiększone powinowactwo do oligonukleotydów oczyszczanych metodą „DMT-ON”. Dzięki przeprowadzonym badaniom w zakresie podłoży hybrydowych, modyfikacji złóż chromatograficznych oraz nowemu reaktorowi przeprowadzimy syntezę demonstracyjną w skali minimum 25 µmola. Wnioski z demonstracji zostaną przeniesione na syntezę oligonukleotydów tak, aby w jednej szarszy technologicznej otrzymać >100mg o czystości >95%. Rosnące zapotrzebowanie na duże ilości oligonukleotydów związane m.in. z wykorzystaniem ich w branży farmaceutycznej (np. terapie antygenowe) czy diagnostycznej (np. testy genetyczne) wymusza podejmowanie działań umożliwiających zagospodarowanie tej niszy. Obecnie na rynku brakuje dostawców oligonukleotydów w ilościach miligramowych/gramowych. „SA.41471(2015/X) Przeznaczenie_pomocy_publicznej: art: 25 rozporządzenia KE nr 651/2014 z dnia 17 czerwca 2014 r. uznające niektóre rodzaje pomocy za zgodne z rynkiem wewnętrznym w stosowaniu art. 107 i 108 Traktatu (Dz. Urz. UE L 187/1 z 26.06.2014)”. (Polish)
0 references
The aim of the project is to increase the synthesis of nucleic acids from 0.2 µmol to 25 µmol, so that synthetic oligonucleotides can be obtained in at least milligram amounts. The goal will be achieved by developing a new type of hybrid substrates in the glass-silan-polymer system for effective large-scale synthesis of oligonucleotides and by simplifying the chromatographic method for the purification of nucleic acids. Synthetic substrates will combine the advantages of solid-phase synthesis and better penetration of reactive sites by the reagents provided by the polymer phase. Thanks to the use of the new synthetic reactor, we will prevent adverse factors occurring in the expansion of the synthesis scale, such as: bonding of the substrate, low penetration, swelling or degradation. By chemical modification of the chromatographic deposit with organo-functional silates, we will obtain an increased affinity for oligonucleotides purified by the “DMT-ON” method. Thanks to the tests carried out in the field of hybrid substrates, modification of chromatographic deposits and a new reactor, we will carry out demonstration synthesis on a scale of at least 25 µmola. The conclusions of the demonstration will be transferred to the synthesis of oligonucleotides, so that in one technological gray it receives > 100 mg with a purity of > 95 %. The growing demand for large amounts of oligonucleotides associated, among others, with their use in the pharmaceutical industry (e.g. antigen therapies) or diagnostic (e.g. genetic tests) forces the taking of measures enabling the development of this niche. Currently, the market lacks suppliers of oligonucleotides in milligram/gram quantities. “SA.41471(2015/X) Purpose of public aid: art: 25 EC Regulation No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L 119, p. That’s it. EU L 187/1 of 26.06.2014)’. (English)
21 October 2022
0 references
WOJ.: WIELKOPOLSKIE, POW.: Poznań
0 references
Identifiers
POIR.01.01.01-00-1877/20
0 references